| 中文名称: | 维多珠单抗 | ||||
|---|---|---|---|---|---|
| 英文名称: | Vedolizumab | ||||
| 别名: | 维多珠单抗 Anti-Human lymphocyte α4β7 integrin, Humanized Antibody | ||||
| CAS No: | 943609-66-3 | ||||
| CAS No: | 943609-66-3 | ||||
基本信息
|
产品编号：V10119 |
|||||
|
产品名称：Vedolizumab |
|||||
|
CAS: |
943609-66-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
分子式： |
|
溶于液体 |
-80℃ |
六个月 |
|
|
分子量 |
|
|
|
||
|
化学名： |
|
||||
|
Solubility (25°C) |
体外 |
DMSO |
|
||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内（现配现用） |
|
|
|||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
生物活性
|
产品描述 |
一种靶向α4β7整联蛋白 (integrin) 的人源化单克隆抗体，用于溃疡性结肠炎和克罗恩病的相关研究。 |
|
靶点/IC50 |
Integrin |
|
体外研究 |
Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%),neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4nM).Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06g/mL) and fibronectin (IC50=0.02g/mL), but not vascular cell adhesion molecule 1. |
|
体内研究 |
Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab.The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5μg/mL in those receiving 0.5mg/kg of vedolizumab and 52.0μg/mL in those receiving 2mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study,the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups. |
推荐实验方法(仅供参考)
|
激酶实验： |
|
Vedolizumab inhibition of high-affinity binding of MAdCAM-1 to human peripheral blood memory CD4+ T lymphocytes is tested.Peripheral blood (90μL) is incubated with a saturating concentration (3μg/mL) of MAdCAM-1-murine-Fc fusion protein and 4mM MnCl2 in a final volume of 100μL for 1 h at room temperature,in the presence or absence of vedolizumab.After washing with assay buffer, the cells are stained with fluorescentlabeled anti-mouse IgG for 15min at room temperature. After washing again, cells are incubated with mouse serum for 10min at room temperature,followed by staining with anti-CD4 and anti-CD45RO antibodies for 15min at room temperature. After washing, red blood cells are lysed with BD FACS lysing solution and analyzed by flow cytometry in a FACSCalibur with CellQuest Pro software. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
